Trinity Biotech (TRIB) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trinity Biotech is the larger company by market cap ($4.9 million vs $2.7 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRIB | VRAX |
|---|---|---|
| Share price | $6.04 | $1.99 |
| Market cap | $4.91M | $2.68M |
| 1-day change | -10.91% | -5.69% |
| EPS (TTM) | $-60.00 | $-11.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.50 | $21.75 |
| 52-week low | $5.01 | $1.83 |
| Distance from 52-week high | -88.50% | -90.85% |
| Average volume | 21.66K | 650.11K |
| Shares outstanding | 813.13K | 1.34M |
| Employees | 287 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Healthcare · Medical Devices · 287 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Healthcare · Biotechnology · 26 employees
TRIB vs VRAX FAQ
Which is bigger, Trinity Biotech or Virax Biolabs Group?
Trinity Biotech (TRIB) is larger, with a market capitalization of $4.91M compared with $2.68M for Virax Biolabs Group (VRAX).
Are Trinity Biotech and Virax Biolabs Group in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Trinity Biotech and Biotechnology for Virax Biolabs Group.